Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures
<p>Abstract</p> <p>Men with metastatic castration-resistant prostate cancer (mCRPC) carry poor prognosis despite the use of docetaxel-based regimens which has modest survival benefit shown by randomized clinical trials. Significant progress in the discovery of novel therapeutic age...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-07-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | http://www.jhoonline.org/content/5/1/35 |